Bristol’s Ixabepilone Granted Priority Review By FDA For Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory action on the epothilone B analog is anticipated in October, Bristol says.
You may also be interested in...
Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod
Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.
Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod
Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.
Bristol To Submit Ixabepilone In First Half Of 2007 For Metastatic Breast Cancer
Firm reports statistically significant Phase III data for ixabepilone/Xeloda combination at American Society of Clinical Oncology meeting in Chicago.